It will still have to go through Phase 3 clinical trials before FDA approval
In patients with HFpEF and obesity, both semaglutide (STEP-HFpEF) and tirzepatide (SUMMIT) significantly reduced cardiovascular death and worsening heart failure events, with concomitant improvements in quality of life and functional capacity [3,47]
Semaglutide GLP-1 injections operate by replicating the actions of a hormone known as glucagon-like peptide-1, or GLP-1, which has a specific influence on brain regions responsible for appetite and food consumption regulation
At Perpetual Wellbeing, we see GLP-1 agonists as one possible tool within a broader, carefully managed health plan
For example, they'll make a liquid version of a brand name pill for a patient who can't swallow pills
GLP-1R causes a reduction in hepatic steatosis and inflammation and increases fat metabolism mediated by increasing hepatic insulin sensitivity [52,53,54]